Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour

Inclusion Criteria: * Patients ≥18 years with selected metastatic solid tumours recognized to be highly vascularised and not amenable to any clinical improvement by current standard treatments * Colorectal cancer (CRC) patients previously resistant to standard systemic regimens (including biologic agents) * Gastric cancer (GC) patients treated with no more than two standard systemic regimens for metastatic disease * Hepatocellular carcinoma (HCC) patients previously resistant to standard systemic regimens * Pancreatic carcinoma (PC) patients treated with no more than one standard systemic regimen for metastatic disease * Non small cell lung carcinoma (NSCLC) patients treated with no more than two standard systemic regimens (including biologic agents) for metastatic disease * Neuroendocrine (NE) tumours refractory to somatostatin analogue treatment * Other rare tumours including malignant pleural mesothelioma (MPM), soft-tissue sarcoma (STS), and renal cell carcinoma (RCC), resistant/refractory to current standard treatments * Life expectancy more than 3 months * ECOG Performance status 0-1 * Adequate baseline bone marrow, hepatic and renal function, defined as follows: * Neutrophils \>1.5 x 10\^9/L and platelets \> 100 x 10\^9/L * Bilirubin \<1.5 x ULN * AST and/or ALT \<2.5 x ULN in absence of liver metastasis * AST and/or ALT \<5 x ULN in presence of liver metastasis * Serum creatinine \<1.5 x ULN * Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50 ml/min * Patients may have had prior therapy providing the following conditions are met before treatment start: * Chemotherapy, radiation therapy, hormonal therapy, or immunotherapy: wash-out period of 28 days * Surgery: wash-out period of 14 days * Patients must give written informed consent to participate in the study. Exclusion Criteria: * Concurrent anticancer therapy * Patients must not receive any other investigational agents while on study * Patients with myocardial infarction within the last six (6) months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication * Uncontrolled hypertension * Prolonged QTc interval (congenital or acquired) \> 450 ms * Patient with significant peripheral vascular disease * History or evidence upon physical examination of CNS disease unless adequately treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with standard medical therapy), or history of stroke * Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol * Known hypersensitivity/allergic reaction or contraindications to human albumin preparations or to any of the excipients * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol * Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of child-bearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration.